The success of GalNAc-siRNA conjugates and LNP formulations is paving the way for future approvals of the multiple siRNA drugs currently in late-stage clinical development to treat diseases such as transthyretin-mediated (ATTR) amyloidosis, primary hyperoxaluria (PH) type 3 (PH3), hemophilia A and B, hyperoxaluria, acute kidney injury (AKI), and ocular pain and dry eye disease [118]. The gene discussed is TTR; the disease is acute kidney injury.